MedTrace Logo

Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants

NCT03993704 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-07-09

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of a daily oral dose of LHF-535 administered for 14 days to healthy participants.

Conditions

  • Healthy

Interventions

DRUG

LHF-535

Oral suspension administered once daily for 14 days

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • Kineta Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-16
Primary Completion
2020-01-09
Completion
2020-06-09

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03993704 on ClinicalTrials.gov